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Abstract: 
 
More than 795,000 Americans suffer a stroke annually, and it is the third leading 
cause of death in the United States1. There are two types of stroke, hemorrhagic and 
ischemic. Hemorrhagic stroke is caused by the rupture of blood vessels within the brain, 
as opposed to ischemic strokes, which are caused by a blockage within the vessel. Of 
all strokes presented clinically, 86% are ischemic by nature1. Currently, there are few 
treatments for ischemic stroke. The prevailing early treatments include thrombolytic 
therapy and antiplatelet therapy such as low dose aspirin2,3. These treatments are each 
flawed. Tissue plasminogen activator (tPA) is currently the only FDA-approved 
thrombolytic therapy for the acute treatment of ischemic stroke4. This treatment is 
approved for less than 10% of patients, and is given to less than 4%4. In addition, 
greater than 65% of hospitals in America have never administered tPA to patients due 
to low efficacy as well as potential harmful side effects5. Antiplatelets, such as low dose 
aspirin, are another treatment option. These are drugs, and therefore have negative 
side effects associated with long-term use such as increased risk of hemorrhagic 
stroke6, and gastrointestinal bleeding7. As a result, there is a distinct lack of safe 
therapeutic options for both the early and long-term treatment of ischemic stroke 
patients.  
Cerebrovascular collaterals refer to the network of blood vessels that are 
clinically documented to perfuse stroke-affected tissue during ischemic stroke and 
reduce brain injury8. While strategies to improve collateral blood flow during stroke are 
of significant therapeutic interest, mechanisms and a means to improve circulation 
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through these blood vessels during stroke remain unknown. This honors thesis proposal 
rests on a key in vivo observation that supplementation of a lesser-characterized natural 
vitamin E, alpha-tocotrienol (TCT), improves cerebrovascular collateral blood flow and 
attenuates stroke injury8. TCT therefore serves as a powerful tool to study 
cerebrovascular collateral remodeling during stroke. The overall objective of this honors 
thesis will be to characterize the effects of TCT on cerebrovascular collateral perfusion 
during stroke and to identify a mechanistic basis for TCT improvement of 
cerebrovascular collateral circulation. Many previously identified arteriogenic markers, 
including Tissue inhibitor of metalloproteinase 1 (TIMP1), will be investigated as a 
known molecular target of interest for induction of collateral growth in the brain. FITC-
lectin tagging of cerebrovascular collaterals will be used for laser capture 
microdissection experiments and downstream molecular study of arteriogenic targets. 
This approach will enable the specific collection of perfused cerebrovascular collaterals 
from stroke-affected tissue for mechanistic study. 
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Introduction: 
Vitamin E: Discovery and Characterization. Vitamin E was discovered in 1922 by 
Herbert Evans9 when he identified phytochemical factors essential for rodent 
reproduction. This work was later continued by Barnett Sure who extrapolated its 
importance  to  humans,  and  named  it  “vitamin  E”  according  to  the  micronutrient  naming 
conventions of the time10. The chemical name assigned for the molecule was 
tocopherol, stemming from the Greek term for  childbirth,  which  is  “tocos”11. Vitamin  E’s  
importance was not fully understood until more modern technology and theory of the 
1950’s  allowed  for  its  elucidation  in  the  context  of  the  developing  field  of  redox  biology. 
 
Palm oil provides the greatest source of a lesser-characterized   vitamin   E   isomer,   α-
tocotrienol, which has antioxidant effects as well as antioxidant-independent health 
benefits shown to affect a broad range of pathological disorders11. Crude palm oil 
contains up   to   800  mg/kg   by  weight   of   the  α-tocotrienol isomer12. Palm oil has been 
documented in human diet as far back as 3000 BC9, but did not become prevalent in 
diet until the early 20th century. The palm oil comes from the fruits of the oil palm tree, 
Elaeis guineensis12. The oil accounts for about 30% of the world’s  total  oil  production13, 
with the most recent annual output of 58.2 million tons14. This oil is primarily produced in 
Southeast Asia15, specifically Malaysia and Indonesia, and is still relatively scarce in 
western diet despite its growing prominence and production on a global scale. This is 
likely due to the oils higher content of saturated fatty acids (SFA) when compared to 
other common vegetable oils16, which is assumed to cause an increase in low density 
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lipoprotein (LDL) cholesterol as increased SFA are known to do17. There is however 
conflicting scientific evidence of this outcome from oil-rich diets18,19.  
 
Today vitamin E is known to consist of eight isomers divided into two families, 
tocopherols as discovered by Evans, and tocotrienols as discovered by Pennock and 
Whittle in 196320. Tocopherols consist of a chromanol ring and a 15-carbon saturated 
tail derived from homogentisate (HGA) and phytyl diphosphate, respectively21. The 
tocotrienols possess the same chromanol head structure, varying only in the carbon tail 
where   they  contain  3   trans  doubles  bonds  at  positions  3’,  7’,  and  11’.  Both  compound  
families  contain  α,  β,  ɣ,  and  δ  isoforms,  differing  in  position  and  degree  of  methylation  
on the chromanol head of the compound (Figure 1). In addition to structural differences, 
a growing body of scientific literature11,21 supports independent biological functions for 
vitamin E family members, some of which are known to be independent of its classically 
defined antioxidant function. 
 
Key differences between tocopherol and tocotrienol family members. When the 
two families are compared, their prevalence in the plant kingdom is unequal. 
Tocopherols as compared to tocotrienols are much more abundant in nature22-24. The 
tocopherols are mainly found in the leaves and seeds of most dicots, and are present as 
the prominent vitamin E component, whereas the tocotrienols are mainly found in the 
seeds of most monocots and a limited number of dicots25. More detailed analysis has 
been done to show that tocotrienols are mainly focused in non-photosynthetic tissue25. 
In light of the unique biological distribution of vitamin E family members, growing 
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evidence supports unique biological function for tocopherols and tocotrienols as well. 
The research that has focused on the lesser-characterized forms of Vitamin E lends 
support   to   unique   biological   function   compared   to   α-tocopherol. Such biological 
functions seen in tocotrienols but not tocopherols include inhibition of HMG-CoA 
Reductase, the same enzyme targeted by the statin class of drugs that is responsible 
for cholesterol synthesis26,27.  Tocotrienol vitamin E has also been reported to inhibit 
growth of human breast cancer28, and protect neurons from ischemic stroke induced 
brain injury29. The study of these lesser-characterized forms of vitamin E remained 
relatively untouched until the past decade. While the most bioavailable form of vitamin 
E,   α-tocopherol, is well studied and has a known selective transport system in 
mammals, little remains known about tocotrienol uptake and transport. It is estimated 
that only 1% of all the vitamin E research produced in the last 30 years pertains to 
tocotrienols11. The current work aims to further the findings of unique, anti-oxidant 
independent functions within the lesser-studied vitamin E isomers. 
 
Research efforts related to ischemic stroke and the process of arteriogenesis have 
increased dramatically over the past twenty-five years. A search of available literature 
using   “ischemic  stroke”  as  a  key   term   in  PubMed   revealed  23,302  publications   in   the  
quarter century period of 1980–2004. By comparison, in the past decade alone there 
have been 34,268 articles published (2005 through February 2014, Figure 2). During 
the same time periods, a PubMed search using arteriogenesis as the key word revealed 
only 202 publications in the twenty-five year period spanning 1980–2004. In the past 
decade, however, there have been 544 published (Figure 3). A similar trend was 
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observed using tocotrienol as a keyword (Figure 4). Taken together, the dramatic 
increase in publication efforts across these distinct disciplines suggests growing clinical 
and patient awareness. As it specifically relates to arteriogenesis, primary literature 
addressing current molecular targets for arteriogenesis has been reviewed for the 
purpose of screening TCT sensitive arteriogenic factors (Table 1). The summarizing 
table is organized by target, and briefly describes their known role in arteriogenic 
remodeling of collaterals.  
 
Tocotrienol and Neuroprotection. The biological significance of vitamin E was 
developed on the basis of its antioxidant function   as   the   body’s   primary lipid soluble 
defense mechanism against oxidative stress and injury30. As the vitamin E family grew 
with the identification of new naturally occurring isoforms (i.e. tocotrienols), so did 
research efforts elucidating antioxidant independent biological function. For example, a 
recent and growing body of research on the lesser-characterized isomer, alpha-
tocotrienol, has identified neuroprotective properties against both glutamate and stroke 
induced neurodegeneration at nanomolar quantities. Importantly, these properties are 
unique to alpha-tocotrienol, as the better-characterized alpha-tocopherol does not 
possess these effects in the nanomolar concentration range29. Any biological activity at 
this concentration cannot be attributed to antioxidant function, as other lipid soluble 
antioxidants are present in brain tissue at much higher quantity11. This observation 
points to specific mechanisms of biological function for vitamin E family members that 
are unrelated to their well-known role as antioxidants.  
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Multimodal Tocotrienol Protection Against Ischemic Stroke. In light of the failure of 
neuroprotective agents in rodent stroke models to translate to clinical success, the TCT-
dependent protection observed in rodent models had to be tested in a large animal 
setting before going to patient trials. Outcomes of a large animal (canine) trial validated 
prophylactic supplementation of TCT for protection of grey and white matter brain tissue 
against acute ischemic stroke31. The study demonstrated a significant decrease in post-
stroke infarct size from those animals supplemented with TCT as opposed to the 
placebo control31. Furthermore, an unexpected finding was uncovered in the canine 
study that was enabled by real-time angiography of cerebral blood flow. Prior to this 
work, cerebral angiography was not investigated in rodent stroke models testing TCT. 
Strikingly, retrospective review of cerebral angiograms identified improved collateral 
blood flow in stroke-affected tissue of TCT supplemented canines as compared to 
placebo controls. Quantitative analyses of collateral blood flow was determined from 
cerebral angiograms using an 11-point clinical scale. Of interest, stroke-induced lesion 
volume correlated tightly with collateral score, such that the canines supplemented with 
TCT had greater collateral blood flow and smaller stroke lesion volumes31. 
 
From here, the current work moves back to small animal models in order to find the 
mechanistic basis for how TCT improves cerebrovascular collateral blood flow and 
attenuates stroke injury. It is hypothesized that the collateral blood flow improvement 
found  from  supplementation  of  α-tocotrienol is a results of arteriogenesis. Arteriogenesis 
refers to the remodeling of pre-existing collateral blood vessels, whereas angiogenesis 
is the growth of new collateral blood vessels altogether. To study the mechanistic basis 
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of improved collateral blood flow via arteriogenesis, previously identified arteriogenic 
factors including tissue inhibitor of metalloproteinase 1 (TIMP1), and matrix 
metalloproteinase 9 (MMP9) were studied as known molecular targets of interest32,33. 
TIMP1 plays the role of inhibitor to the MMP family. The MMP family of peptidases is 
known to break down the proteins that keep the endothelial cells intact, therefore the 
hypothesis is that inhibition of the family results in arteriogenesis and increased blood 
flow. Increased MMP activity is assumed to lead to tipping the balance towards a pro-
proteolytic environment causing a decrease in mature collaterals, while increased TIMP 
expression will cause decreased MMP activity, and henceforth lead to an anti-
proteolytic environment where there is an increase in mature collaterals. Indeed, it has 
already been published that cerebral arteriogenesis induced by stroke causes an up-
regulation of TIMP1 in collaterals31,33. Outcomes from our canine work support this 
claim following 10 weeks of prophylactic TCT supplementation. The current work seeks 
to determine earlier changes in pro-arteriogenic target gene expression, including 
TIMP1 and the aforementioned targets listed in Table 1. Briefly, mice were 
supplemented prophylactically with TCT or vehicle placebo for 4-6 weeks prior to 
mechanical occlusion of the middle cerebral artery to cause ischemic stroke in primary 
somatosensory cortex. We describe a new technique to label collaterals during 
ischemia and leverage experience with laser capture microdissection to selectively 
measure gene expression of arteriogenic targets in collected perfused collaterals. 
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Table 1. Primary literature reviews on arteriogenic factors 
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Methods: 
 
Animal Supplementation. All experiments were approved by the Institutional Animal 
Care and Use Committee of the Ohio State University. Upon arrival, twelve C57BL/6 (5-
week old, Harlan, Indianapolis, USA) mice were allowed to acclimate to their home cage 
environment for 1 week prior to supplementation. At the start of supplementation, mice 
were randomized to one of two groups (n=6). Group one received supplementation for 4 
weeks and group two received supplementation for 6 weeks. Mice were maintained 
under standard vivarium conditions (22±2°C with 12:12 dark: light hour cycles). Within 
groups, mice were evenly divided to receive placebo control (n=3) or TCT (n=3) 
supplementation. The placebo group was orally gavaged five days a week with vitamin 
E stripped corn oil using a volume matched to the mean of TCT supplemented mice 
(Figure 5). The test group was orally gavaged with TCT (Carotech, Malaysia) in vitamin 
E-stripped corn oil at a dosage of 50 mg/kg body weight as reported previously29. 
Surgery was performed at 24h after the last supplementation. 
 
Surgery. Acute ischemic stroke was induced using the intraluminal suture method of 
middle cerebral artery occlusion (MCAO) as described previously29 (Figure 6). 
Transient focal cerebral ischemia was induced in mice following 4 or 6 weeks of 
supplementation. The mice were anesthetized with 1 to 1.5% isoflurane delivered by 
medical air (21% O2, balance N2). A monofilament nylon suture (6-0) was advanced into 
the internal carotid artery by way of the external carotid artery. The filament tip was 
directed until slight resistance was felt (∼8mm). Cortical blood flow was continuously 
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monitored during surgery using laser Doppler flowmetry (LDF). Successful MCAO was 
confirmed by a >70% reduction in relative blood flow in the MCA supplied cortex. Once 
MCAO was validated, the mice remained under anesthesia for 30min until FITC-lectin 
perfusion was performed while MCAO-induced ischemia persisted. 
  
Validation of acute ischemic stroke surgical model. Acute ischemic stroke is caused 
by an abrupt and sudden occlusion of a large vessel which arrests cerebral blood flow 
and the delivery of blood borne nutrients including oxygen and glucose to brain tissue. 
To model this phenomenon in vivo, we employed the intraluminal suture method of 
middle cerebral artery occlusion (MCAO, as depicted in Figure 6 of methods). This 
approach induces ischemic stroke by mechanical occlusion of the MCA using a 6-0 
nylon filament suture29. As real-time cerebral angiography is not enabled in our rodent 
model, we rely on laser Doppler flowmetry (LDF) to validate successful MCA occlusion. 
To acquire LDF from the occluded MCA territory, a 5mm incision is made in the scalp 
for intracranial LDF probe placement. The probe is placed in the primary somatosensory 
(S1) cortex using a small screw affixed with cyanoacrylate. LDF produces continuous 
light (785nm), and gives measurements in arbitrary perfusion units (pfu). In order to 
determine the decrease in blood flow using LDF, before the suture is inserted into the 
middle cerebral artery, cortical blood flow is monitored to establish a pre-stroke 
baseline. Once MCAO is successfully performed, blood flow is continuously monitored, 
and successful occlusion is confirmed by a >70% reduction in relative blood flow as 
compared to baseline. The table shown gives an exact percentage decrease in cortical 
blood flow seen by each animal during surgery, conferring successful stroke in each. 
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FITC-Perfusion. FITC-conjugated lectin (tomato Lycopersicon esculentum, Vector 
Laboratories) was perfused during ischemia to visualize perfused collaterals of the 
stroke-affected S1 cortex for use with laser capture microdissection experiments and 
downstream molecular study. Mice remained anesthetized with isoflurane (1%–1.5%) in 
medical air and FITC-lectin perfusion was performed while the MCA remained occluded. 
Delivery of FITC-lectin particles during cerebral ischemia was achieved by intracardial 
injection (250μL FITC-lectin) 30mins after the onset of MCAO. FITC-lectin was allowed 
to circulate systemically for 5min after which deeply anesthetized mice were decapitated 
and brain tissue collected and embedded in OCT (Sakura, Torrance, CA, USA). 
Cerebellum brain tissue was snap frozen in liquid nitrogen for downstream HPLC 
determination of vitamin E content. 
 
Vitamin E Extraction and Analysis Using High Performance Liquid 
Chromatography. Vitamin E extraction (Table 2) and analysis of mouse brain tissue 
was performed as previously described using an HPLC-coulometric electrode array 
detector (Coularray Detector, 12-channel, model 5600, ESA, Chelmsford, MA, USA) 
(Figure 7). This system enables the simultaneous detection of five naturally occurring 
vitamin E family members in a single run34 (Figure 8), including alpha-tocopherol, 
gamma-tocopherol, alpha-tocotrienol, gamma-tocotrienol, and delta-tocotrienol. 
 
Immunohistochemistry and imaging. At the time of euthanasia, mouse cerebral 
hemispheres were sliced in the coronal axis using a brain matrix (Ted Pella, Inc.) and 
23 
 
embedded in OCT (Figure 9). OCT-embedded frozen brain tissue was sectioned 
(10μm) using a cryostat (CM3050s, Leica Microsystems, Buffalo Grove, IL, USA) and 
mounted on positive-charged slides. Immunohistochemical staining of sections was 
performed as described35 using CD31 (1:200; BD Pharmingen, San Diego, CA, USA) 
primary antibody to label all blood vessels in the stroke-affected hemisphere regardless 
of whether they were perfused. Secondary antibody detection and counterstaining were 
performed as described previously35. The entire stroke-affected hemisphere was 
imaged using fluorescent microscopy36. Perfused collaterals were quantified from FITC-
lectin labeled vessels and expressed as percent area of the entire hemisphere. Total 
blood vessels in the stroke-affected hemisphere were quantified from all CD31 labeled 
blood vessels. 
 
Laser Microdissection Pressure Catapulting and RNA isolation. For laser capture 
microdissection, OCT-embedded brain tissue was sliced into 12µm thick sections using 
a cryostat. Sections were mounted onto RNase inhibitor-treated thermoplastic 
(polyethylene napthalate)-covered glass slides (PALM Technologies, Bernried, 
Germany). In this work we refer to collaterals as FITC-lectin perfused vessels isolated 
from stroke-affected primary somatosensory (S1) cortex. FITC-lectin labeled collaterals 
from the stroke-affected primary somatosensory cortex were collected using a PALM 
MicroLaser, MicroBeam, and RoboStage/RoboMover system (Figure 10). More than 
150,000µm2 of capture elements were collected (Table 3) for downstream RNA 
isolation, cDNA synthesis and real-time PCR. After laser cutting, the isolated collaterals 
were  catapulted  directly  into  35μl  of  RNA  extraction  buffer  (PicoPure RNA Isolation kit; 
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Life Technologies, Grand Island, NY, USA) situated directly above the section in a 
microtube cap. An additional 15μl  of  extraction  buffer  was  added  after  collection. RNA 
was isolated from captured and catapulted elements using the PicoPure RNA Isolation 
Kit as described37.  
 
Real-Time PCR. Gene expression levels of arteriogenic targets were independently 
determined at 24 hours from contralateral control and stroke-affected laser 
microdissection pressure catapulting-captured elements using real-time PCR, as 
previously described37. Total RNA was reverse transcribed into cDNA using oligo-dT 
primer and Superscript III (Life Technologies, Grand Island, NY, USA). Reverse 
transcriptase-generated DNA was quantified by real-time PCR assay using double 
stranded DNA-binding dye SYBR Green-I (Life Technologies, Grand Island, NY, USA) 
with custom made primers (Integrated DNA Technologies, Coralville, Iowa, USA). All 
primer sequences have been provided (Table 4). 
 
Statistical Analysis. Statistical analysis of data was performed using Microsoft Excel 
software (v12.3.6). All data are reported as mean ± standard deviation. Difference 
between means was tested using Student's t-test (p<0.05). 
 
A timeline is provided to clarify the chronological steps of the study (Figure 11). 
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Results: 
 
Verification of results in a rodent model. Informed by our canine study, we repeated 
10 week supplementation studies in mice to specifically look at cerebral blood flow in 
the brain during ischemic stroke. As in canine, 10 week prophylactic supplementation of 
TCT in mice significantly attenuated stroke induced lesion volume (Figure 12). 
Collateral blood flow was studied in these mice using laser speckle flowmetry imaging. 
Results show that 10 week TCT supplementation is successful at increasing cerebral 
blood flow to the stroke-affected region (Figure 13). On the basis of these outcomes, 
the current work was designed to test expression of pro-arteriogenic factors at earlier 
time points (4-6 weeks) to determine whether the TCT-mediated change in 
arteriogenesis was an acute response (at the time of MCAO) or the result of chronic 
changes over the course of supplementation. 
 
Brain vitamin E levels following prophylactic TCT supplementation. Given the 
natural variation in mouse development and body weight, mice were weighed weekly 
and TCT gavage dose was adjusted accordingly to achieve a concentration of 50mg/kg 
body weight. To account for variability in the amount of brain tissue collected at 
euthanasia, vitamin E content was normalized to brain protein content (pmol vit E/mg 
protein). Protein quantification was performed using the bicinchoninic acid assay (BCA, 
Figure 14). The BCA protein assay is a biochemical assay used to determine total 
protein concentration. The assay is colorimetric, meaning it relies on the detection of 
light absorbance at 562nm in order to determine protein concentration by comparison to 
36 
 
a standard. This technique was used to determine brain tissue protein content for each 
mouse. Subsequently, vitamin E levels determined by HPLC were normalized to brain 
protein concentration. Figure 15 demonstrates that TCT supplementation enriched 
brain tissue with α-tocotrienol by 12.09 nmol/g protein. The murine diet provided is 
deficient in all tocotrienols, resulting in the detection of no significant amount of 
tocotrienol in brain tissue of the PBO controls using HPLC-coulometric electrode array 
detection. Of note, the concentration of brain α-tocotrienol in TCT-supplemented 
animals was 12.3 times less than that of α-tocopherol in the cerebellum, which 
represents the most bioavailable vitamin E isoform found in the body (Figure 15). This 
outcome is in line with known uptake mechanisms for alpha-tocopherol by the 
tocopherol transfer protein (TTP), which has an 8.5-fold greater affinity for tocopherols 
versus tocotrienols38, though this may vary based upon tissue type39,40. TCT 
supplementation also modestly increased the concentration of α-tocopherol in brain 
tissue as compared with PBO controls. Our TCT supplement, while highly enriched with 
alpha-tocotrienol, is only 70% pure, the remainder of which contains other vitamin E 
isoforms, including alpha-tocopherol. Taken together, results demonstrate that mice 
orally supplemented with TCT for only 4-6 weeks significantly increased the 
concentration of tocotrienols in the brain as compared to PBO controls. 
 
Tocotrienol supplementation increases collateral perfusion during acute ischemic 
stroke. Our recently published observation31 that prophylactic TCT supplementation 
improved cerebrovascular collateral circulation during stroke uncovered new putative 
mechanisms for TCT protection against stroke injury. This observation was enabled by 
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a large animal (canine) endovascular stroke model that employed real-time cerebral 
angiograms for documentation of cerebral perfusion during stroke. The canine study 
revealed, through the retrospective study of angiograms, that collateral blood flow had 
improved in the TCT supplemented canines. Angiograms revealed improved collateral 
blood flow, allowing for retrograde filling of occluded parent vessels through 
anastomosing collaterals (Figure 16). To confirm results, a physician was shown the 
angiograms to objectively assess the collateral blood flow seen in each subject on an 
11-point scale of the stroke-affected hemisphere. The physician, blind to the study, gave 
significantly higher scores to the supplemented group when compared to the placebo. 
This increased collateral blood flow is thought to be the reason for decreased infarct 
volumes seen within the canine study. Until this work, TCT had been described to 
attenuate stroke-induced injury on the basis of neuroprotection alone29. In light of cost, 
molecular reagent availability, and low-throughput surgeries associated with the canine 
stroke model, we sought to develop tools to test mechanistic hypotheses of TCT-
induced arteriogenesis in a small animal (murine) stroke model. To visualize cerebral 
perfusion in mouse during MCAO, fluoroscopic angiograms are not a viable option. We 
therefore developed the following immunohistochemical approach to visualize cerebral 
perfusion during acute ischemic stroke. During ischemia, mice were injected with FITC-
conjugated lectin, sections of the same brain were also immunostained using CD31, a 
marker of endothelial cells41. This lectin compound, a carbohydrate binding protein 
aiding in molecular recognition specific to sugar moieties, is derived from tomato. The 
name lectin itself is derived from the Latin term legere, which means “to   select”.   The  
particular lectin used here binds selectively to perfused endothelial cells, allowing 
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visualization of structures in the microvasculature when viewed by fluorescent 
microscopy, refer to Figure 10. To stain all endothelial cells in brain tissue, regardless 
of perfusion, we employed CD31 immunostaining. CD31 is an immunoglobulin 
superfamily member. As an immonglobulin, CD31 mediates adhesion and trans-
endothelial migration of T-lymphocytes into the vascular wall, as well as T cell activation 
and angiogenesis. CD31 is localized on the surface of endothelial cells42. Using these 
two staining methods in combination allows for relative quantification of total vasculature 
and perfused vasculature during ischemia (Figure 17). These images are then 
compared and merged in order to show the change in perfused collateral blood flow of 
the stroke-affected region of the brain, but not an overall increase in number of total 
blood vessels present in the brain, lending credence to the process of arteriogenesis. 
Quantification showed that prophylactic TCT supplementation significantly increased 
lectin perfusion in the S1 cortex by 2.3 fold (p=0.01) following 4+ weeks 
supplementation.  
 
Endothelial cell specific laser capture microdissection (LCM) from brain tissue. A 
major obstacle with studying brain vasculature is the contamination of other cell types in 
collected tissue, such as neuron or glial cells. To avoid such contamination in collected 
tissue samples, a technique known as laser capture microdissection (LCM) was 
employed that enables site and cell specific resolution of tissue biology. This approach 
allowed for selective capture of blood vessels from brain tissue using an LCM 
microscope guided by FITC-lectin tagged endothelial cells of perfused vessels. Laser 
captured collection yield (Table 3) shows the area of collected tissue from each 
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samples, separating the stroke affected and contralateral sides for separate analyses. 
With these tissue samples collected, RNA isolation was then performed using the 
PicoPure RNA Isolation kit (Arcturus, Mountain View, CA, USA). Initial analysis of the 
RNA was determined using a NanoDrop spectrophotometer (NanoDrop Technologies, 
Wilmington, DE). The machine provided nucleic acid concentrations, as well as purity 
information in the form of 260/280 and 260/230 ratios to determine protein or other 
contaminants presence in the sample (Table 5). The ratio of 260/280 gives the 
absorption found at 260nm light and 280nm. The nucleic acids absorb light best at 
260nm, while proteins and phenols, which are commonly used in RNA extraction, 
absorb light strongly at 280nm. The same principles hold true for the 260/230 ratio, as 
thiocynates, carbohydrates, some phenols, and other organic compounds best absorb 
light at 230. While an acceptable 260/280 ratio is between 1.8-2.0, our values were 
consistent with the collection range for laser capture microdissection of ~1.531. 
 
Screening for TCT sensitive arteriogenic markers. Arteriogenesis refers to a positive 
outward remodeling of pre-existing collateral arteries into larger vessels, which are able 
to circumvent sites of occlusion and perfuse otherwise stroke-affected tissue33,43. To 
determine whether TCT supplementation invoked molecular mechanisms of cerebral 
arteriogenesis at an earlier (4-6 week) time point, endothelial cells from the stroke-
affected and contralateral control cerebral cortex were selectively isolated and prepared 
for PCR analysis. With prepared tissue, PCR analysis was used to confirm collection of 
endothelial cells, using von Willebrand factor (vWF) as a endothelial cell marker, glial 
fibrillary acidic protein (GFAP) as a glial cell marker, and neurofilament heavy 
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polypeptide (NFH) as a marker for neurons8 (Figure 18). Of interest were multiple 
markers previously indicated to play a key role in the process of arteriogenesis44. 
Previously identified markers includes; matrix metalloproteinase family members 
(MMP2, MMP9), tissue inhibitor of metalloproteinase family members (TIMP1, TIMP2), 
chloride intracellular channel family members (CLIC1, CLIC4), Krüppel-like Factor 2 
(KLF2), cluster of differentiation variant 3 (CD44v3), P300/CBP-association factor 
(PCAF), and Shc1 sensitive targets (EphrinB2 and delta-like 1 and delta-like 4). For 
quick reference of arteriogenic targets, refer to Table 1. 
 
Matrix metalloproteinases (MMP) 2 and 9 have previously been identified as key 
contributors within the process of arteriogenesis44. MMPs are a family of zinc-dependent 
endopeptidases which are able to break down extracellular matrix45. MMP2 and MMP9 
belong to a class of MMPs known as gelatinases, which are unique from the other 
MMPs in their role as proteolytic enzymes. This class is capable of breaking down 
gelatin and type IV collagen found in the basal lamina, a layer of extracellular matrix 
secreted by the endothelial cells. Due to this activity, the role of gelatinases is critical for 
the remodeling of vessels. Our data shows this family is responsive to TCT 
supplementation, with MMP2 mRNA being down-regulated significantly (2.46x 
decrease, p=0.002, Figure 19), and MMP9 showing a trend towards down-regulation as 
well (2.51x decrease, p=0.68, Figure 20), though the results were not statistically 
significant. 
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Of specific interest during our project were TIMP1 and TIMP2, for their previously 
identified roles as inhibitors of MMPs, aiding in the process of collateral remodeling via 
arteriogenesis33. These genes and their products fall within a family known as tissue 
inhibitor of metalloproteinase (TIMP). This family of genes encode for proteins of the 
same name, which are natural inhibitors of the matrix metalloproteinases (MMPs). 
TIMP1 and TIMP2 were chosen for study, as they are known inhibitors of MMP2 and 
MMP9. With their ability to function as inhibitors of these MMP peptidases, the TIMP 
family is known to play an important role as the regulator of MMPs in the brain. Previous 
work has shown that TIMP1 gene regulation is responsive to TCT supplementation31. 
Our findings here report a down-regulation of TIMP1 in the collected tissue samples 
(2.49x decrease, p=0.01, Figure 21), which confirm sensitivity to supplementation, while 
TIMP2 was not significantly affected (1.67x increase, p=0.17, Figure 22).  
 
Previous work identified chloride intracellular channel (CLIC) 1 and 4 to be up regulated 
by supplementation of TCT31. These CLICs belong to a group of genes and their protein 
products that regulate processes including stabilization of cell membrane potential, 
transport across the epithelium, cell division, apoptosis, and cell motility46,47. The CLIC 
proteins are thought to influence the process of arteriogenesis by acting upstream of 
other genes relevant for vascular growth, including hypoxia-inducible factor-1α,  vascular  
endothelial growth factor-A (VEGF-A), and angiopoietin-248. CLIC1 and CLIC4 have 
been shown to be sensitive to TCT supplementation31. The CLIC family is also known to 
play an important role in the process of cell hallowing and widening, known as 
tubulogenesis, which is critical for functional arteriogenesis49,50. Data collected in this 
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study showed no changes in mRNA expression of either CLIC1 (1.67x decrease, 
p=0.22, Figure 23) or CLIC4 (1.58x increase, p=0.20, Figure 24) markers at the earlier 
4-6 time point for collection.  
 
Krüppel-like Factor 2 is a newly identified arteriogenic marker51, it is understood to be 
induced by shear-stress, resulting from laminar flow of blood through the vascular 
tissue. The increased gene expression within the endothelial cells leads to anti-
inflammatory response due to inhibiting activation of p65, anti-thrombolytic effect 
caused by up-regulation of endothelial nitric oxide synthase and thrombomodulin, and 
anti-angiogenesis properties via inhibition of vascular endothelial growth factor (VEGF) 
receptor 252. It is understood to be crucial in vascular development, with previous 
research showing that knockout mice die around embryonic day 13 due to severe 
embryonic hemorrhaging53,54, and thus is thought to be critical in vessel development 
and integrity throughout life. Importantly, this work is the first to determine whether KLF2 
mRNA expression is TCT sensitive. Results of this study have shown that TCT 
supplementation causes a trend of moderate down-regulation in KLF2 that is very close 
to statistical significance (3.29x decrease, p=0.08, Figure 25). We hypothesize that this 
down-regulation would be significant if supplementation persisted to the 10 week time 
point. Statistical significance may be reached at the 4-6 week time point if the study 
were better powered. 
 
Previous work has indicated that during the process of arteriogenesis, both total CD44 
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as well as CD44 variant 3 (CD44v3) are up regulated and result in improved 
arteriogenic outcomes55. The gene encodes for a cell-surface glycoprotein, specifically 
involved in cell-to-cell interactions, cell adhesion and migration. The protein functions as 
a receptor to hyaluronic acid and other ligands, such as osteopontin, collagens, and 
MMPs. This interaction with the MMP family is hypothesized as the connection between 
these surface proteins and the process of arteriogenesis. CD44v3 is one of many 
variants that arise from the transcription of this gene as transcripts undergo complex 
alternative splicing that results in many functionally distinct isoforms56. This glycoprotein 
has  not  been  studied  in  previous  TCT  supplementation  projects,  and  as  such  the  gene’s  
sensitivity to TCT was unknown. Though screened here, no data resulted from the 
testing (Figure 26). We conclude that expression was either very low, or that 
amplification did not result due to poor primer design. Further testing with new primer 
design is required. 
 
K (lysine) acetyltransferase 2B (KAT2B), also known as P300/CBP-associated factor 
(PCAF), is a transcriptional co-activator associated with the p53 protein. This protein 
has recently been indicated as playing a large role in arteriogenesis57. PCAF has 
histone acetylating activity and promotes transcription of multiple inflammatory genes. 
As arteriogenesis is an inflammatory driven process, PCAF is seen as a multi-factorial 
regulator of this process through its regulation of inflammation. To confirm, recent 
studies have shown that in mice, PCAF deficiency reduced the in vitro inflammatory 
response in leukocytes and vascular cells involved in arteriogenesis interrupting the 
process significantly.   We   had   not   previously   study   this   gene,   so   it’s   sensitivity   to  
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supplementation is unknown. Results showed no alteration in the expression of PCAF 
mRNA within the samples (p=0.86, Figure 27). 
 
Shc1 is a gene that holds an important function in the process of arteriogenesis. The 
gene is activated by the onset of shear stress and integral in two pathways necessary 
for the arteriogenic process to be successful58. Shc1 knockout mice have impaired 
activation  of  the  nuclear  factor  κ-light-chain-enhancer of activated B-cell (NF-κB)-
dependent inflammatory pathway59. Additionally, Shc1 is required for shear-stress 
mediated arteriogenic remodeling and induces up-regulation of the endothelial cell 
marker ephrinB2 and activation of the Notch pathway by ligands delta-like 1 (DLL1) and 
delta-like 4 (DLL4). To test whether targets of the Shc1 pathway were sensitive to TCT 
supplementation, we assessed gene expression of EphrinB2, DLL1, and DLL4. 
EphrinB2 is a target gene of the notch pathways, and was studied to identify a change 
in notch pathway activity. EphrinB2 was shown to significantly decrease in mRNA 
expression due to TCT supplementation (1.72x decrease, p=0.01, Figure 28). To 
further this pathway, ligands of the notch pathway were also analyzed. These ligands 
include delta-like 1 and delta-like 4. In these ligands, we saw no significant change and 
an increase respectively. Results show delta-like 1 change being statistically 
insignificant (6.44x increase, p=0.19, Figure 29), while delta-like 4 was significant 
(3.96x increase, p=0.04, Figure 30). The genetic markers studied here have all been 
consolidated into a schematic diagram to better represent their role in the process of 
arteriogenesis (Figure 31). 
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Discussion: 
 
The motivation for ischemic stroke research is driven by the paucity of clinically 
available therapies for stroke patients. While a number of stroke therapies have shown 
promise in pre-clinical testing, few have proven effective in a clinical setting60. A recent 
review of 8,516 stroke related studies identified 1,026 candidates in pre-clinical testing 
that showed promise for treatment of ischemic stroke61. To date, each of these have 
fallen short in clinical trials62. Due to this grave need for therapeutic options to treat 
ischemic stroke patients, we set about testing TCT against ischemic stroke. Our lab has 
been studying tocotrienol vitamin E isoforms in the context of neuroprotection against 
ischemic stroke for over a decade11,21,29,31,37,63-73. As a natural vitamin, humans have 
safely consumed tocotrienols as part of a complex diet for centuries74,75. The most 
abundant natural source of TCT vitamin E comes from palm oil. Palm oil is 
predominantly produced in Malaysia and Indonesia, which account for around 85% of 
the  world’s  palm  oil76.  As  the  world’s  principal  producer  of  palm  oil,  the  palm oil plant is 
significant to the agriculture and economy of both Maylasia and Indonesia. In Malaysia 
the palm oil industry accounts for 3.2% of the national GDP and 6 to 7% of the national 
GDP in Indonesia77. Recently, palm oil derived tocotrienol vitamin E has been granted 
Generally Recognized As Safe (GRN No. 307) certification by the United States Food 
and Drug Administration (U.S. FDA) for use as a food ingredient78. In light of a robust 
safety profile and growing body of research testing mechanisms of both neuro- and 
vascular-protection, we have begun clinical testing of tocotrienol vitamin E in patients 
who already suffered a sentinel ischemic stroke (see NCT01578629 on 
67 
 
clinicaltrials.gov). This patient population is at high risk for a second stroke event within 
one year of their first stroke episode, therefore serving as an ideal population of study 
for a prophylactic intervention such as TCT. This work, returns to pre-clinical testing to 
elucidate mechanisms of the vascular protective properties of TCT against acute 
ischemic stroke. Outcomes may direct future clinical trial designs that specifically target 
vascular protective intervention, such as catheter based delivery or long-term 
prophylactic dietary supplementation.  
 
In light of the failure for putative stroke therapeutics that found success in rodent pre-
clinical testing but failed in human clinical trials, we sought to test TCT against ischemic 
stroke in a large animal model that more closely approximated the human stroke 
condition. The mongrel canine stroke model required two small femoral artery 
punctures, followed by insertion of a platinum embolic coil to occlude the middle 
cerebral artery, as confirmed by c-arm fluoroscopy79. This testing showed that TCT 
does attenuate stroke-induced injury in a canine brain that more closely approximates 
that of a human. This study also uncovered an important clue into a previously unknown 
mechanism for TCT protection against stroke-induced brain injury. Specifically, cerebral 
angiograms enabled in our large animal setting demonstrated that TCT but not placebo 
treated canines possessed increased collateral blood flow in the stroke hemisphere. 
This observation was the first to identify a TCT-dependent vascular protection 
mechanism against stroke-induced injury31. As no new vessels were seen within the 
angiogram, the protection was understood to take place via remodeling of pre-existing 
collaterals, a process referred to as arteriogenesis. On the basis of this observation, we 
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move back to the mouse in order to more easily study the mechanisms of collateral 
remodeling identified in our large animal, canine stroke model. The mouse is better 
suited for this study because of decreased cost associated with the model, increased 
availability of test subjects, and access to molecular biology reagents for testing 
purposes. 
 
Our first step when moving to a mouse model was to validate the improvement in 
collaterals observed in canine testing. To do so, an identical supplementation 
experimental design was employed for mice. They were supplemented for 10 weeks, 
then given stroke and compared to their placebo counterpart for both infarct volumes as 
well as blood flow to the stroke-affected hemisphere. Real time angiography was not 
feasible in mouse, as their smaller size limits fluoroscopy exposure. Therefore, in order 
to verify an increase in blood flow, laser speckle contrast imaging was employed. Laser 
speckle contrast imaging work by shining a laser on the surface of the cortex, causing 
the light to scatter and produce a speckle pattern that can be captured by a camera. 
Analysis   of   the   speckle   pattern   leads   to   a   so   called   “speckle   contrast”,  which   is   then  
related to a measure of blood flow for each area of the cortex80,81. Results showed that 
10 week prophylactic TCT significantly increased blood flow in the stroke-affected tissue 
as compared to PBO supplemented controls. Furthermore, stroke-induced lesion 
volume was attenuated as measured by 11.7T MRI. These outcomes were consistent 
with results observed in our published canine work31 (Figures 30, 31). 
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From here we began to study the mechanistic basis for this arteriogenic 
cerebrovascular remodeling we had seen in both the canine and mouse model. One of 
the first questions that arose was the time frame of supplementation required for this 
process to be effective. As we observed successful remodeling and improved collateral 
circulation during stroke in mice supplemented with TCT at 10 weeks, we elected to 
also study an earlier time frame of 4-6 weeks to detect earlier changes in gene 
expression that may affect the long acting improvement in blood flow during stroke. 
Originally, we had proposed to separate the two groups into separate time points and 
compare the two, however there was no significant different in vascular changes seen 
between the groups, so they were joined together as one earlier time point trial. By 
doing this, we aimed to shed light on the temporal resolution of the arteriogenic 
transcriptome, by comparing pro-arteriogenic markers studied at the 10 week time point 
of the published canine study to the 4-6 week time point. In addition to the few genetic 
markers studied in the 10 week study, we also identified new pro-arteriogenic 
candidates for their sensitivity to TCT supplementation after 4 weeks. 
 
Importantly, this is the first work to test vitamin E levels in brain as early as 4 weeks 
after start of supplementation. Results revealed that the concentration of alpha-
tocotrienol in brain after one month of supplementation is sufficient to afford 
neuroprotection on the basis of previously published work39,67. We hypothesize that this 
amount is also adequate to induce vascular remodeling. As it relates to vascular 
protection here, TCT supplementation significantly decreased TIMP1 expression in 
perfused vessels of the stroke-affected  primary  somatosensory  cortex.  TIMP1’s  ability  
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to control extracellular matrix degradation and advancing vascular remodeling by the 
activation of cell proliferation represents an important role in arteriogenesis33. The 
observation that this supplementation may decrease TIMP1 expression in the blood 
vessel of stroke-affected hemisphere points to the possibility that oral supplementation 
of TCT may prime the cerebral vasculature, enabling arteriogenesis in response to an 
ischemic event in the cerebral cortex. Our understanding is that the onset of the 
arteriogenic remodeling process is marked by an initial decrease in expression of the 
protease inhibitor TIMP1. The targets of TIMP1, MMP2 and MMP9, belong to a class of 
MMPs known as gelatinases, which are unique from the other MMPs in their role as 
proteolytic enzymes. This class is capable of breaking down gelatin and type IV 
collagen found in the basal lamina, a layer of extracellular matrix secreted by the 
endothelial cells82,83. This process requires break down of the basal lamina to increase 
vessel diameter. Proteolysis of the internal and external basal lamina by MMPs is 
essential to overcome the structural barriers to growth84-87. The controlled breakdown of 
this vascular framework allows for the expansion and outward growth of collateral 
vessels32, necessary for remodeling. Though previous work has suggested that at 10 
weeks TIMP1 is significantly increased31,33, our outcomes point to an acute phase 
decrease in TIMP1 that allows for more MMP2 and MMP9 gelatinase activity. This early 
response likely aids the remodeling process, while a late-phase (i.e. 10 weeks) increase 
in TIMP1 would help stabilize the functional vessel and prevent further remodeling or 
other break down leading to leakiness within the vessel. Overall, this work provides 
further evidence of TCT supplementation regulating TIMP1 expression and 
subsequently invoking cerebrovascular arteriogenesis. 
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In addition to TCT supplementation exerting influence over the proteolytic environment 
during cerebrovascular remodeling, it also appears to affect shear stress and related 
mechanotransduction signaling involved in the process of arteriogenesis. Previous work 
identified Shc1 as a shear-stress sensitive inducer of arteriogenesis59. Phosphorylated 
Shc1 adaptor protein is responsible for activating multiple tyrosine kinases, including 
Ras and MAPK which are believed to induce transcriptional activation of Notch ligands 
(i.e. Delta-like ligands 1 and 4)59,88,89. Shc1 is required for shear stress induced 
activation of these targets59, so to indirectly study this adaptor protein we assessed 
mRNA expression of mechanotrasnduction-sensitive notch ligands, including DLL1 and 
DLL4. Interestingly, our results show DLL4 mRNA is significantly up-regulated (3.96x 
increase) by TCT supplementation, while DLL1 shows a trend of increased expression 
(6.44x increase, p=0.194). It would be expected that an increase in DLL1 and DLL4 
mRNA expression would drive a concomitant increase in ephrinB2 expression. Here, no 
such effect was observed, suggesting the following possible explanations: (1) the time 
point for collection preceded DLL1 and DLL4 dependent induction of ephrinB2 in the 
notch signaling pathway, (2) post-transcriptional silencing of ephrinB2 by unknown 
mechanisms, (3) post-translational degradation of DLL1 and DLL4 protein, or (4) 
interference of DLL1/DLL4 notch ligand binding. Recent research on DLL1 and DLL4 
show they have separate function. Pertinent literature shows that DLL1 is essential for 
proper function of shear stress induced arteriogenesis in the post-natal mouse90, while 
DLL4 is only expressed in microvessels of the post-natal mouse, or all vessels during 
embryonic development91. In this light, TCT-dependent induction of DLL4 suggests two 
72 
 
possibilities: (1) that the majority of laser captured elements were smaller microvessels 
(capillaries, Ø<10µm Æ arterioles, Ø=10-50µm), or (2) that TCT supplementation is 
leading   to   a   “reprogramming”   of   endothelial cells, awakening normally dormant 
embryonic development genes such as DLL4. Overall, we hypothesize that an increase 
in Shc1 expression has occurred, due to the up-regulation of its closest studied 
downstream targets, DLL1 and DLL4. On the basis of these results, there is a clear 
need to study molecular target upstream of the delta-like ligands, specifically Shc1. To 
gain a better understanding of the role TCT supplementations is playing here, analysis 
of Shc1 mRNA and protein is required. To do so, Shc1 mRNA expression can be tested 
using real-time quantitative-PCR, protein expression can be tested using either Western 
Blot techniques or immunohistochemical staining, and finally protein activity can be 
determined by stoichiometric quantification of phosphorylated enzyme (active) 
compared to un-phosphylated enzyme (inactive)92. Due to the findings here, future 
experiments will address the notch signaling pathway in greater detail to further uncover 
the role it plays in shear stress induced arteriogenesis. 
 
In addition to DLL1, DLL4, and ephrinB2, we investigated another pro-arteriogenic 
target known to be induced by shear stress and mechanotransduction signaling. KLF2 
acts as an important transcriptional regulator of many processes within the body 
including cell proliferation, apoptosis, differentiation and development93,94. Relevant to 
this study, KLF2 is known as a shear stress-induced transcription factor capable of 
activation many proteins95. Critically, these proteins have anti-inflammatory as well as 
anti-coagulant properties. KLF2 is able to respond to shear stress by binding of 
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transcription factors to its promoter region. Many of the transcriptional factors are 
components of the shear stress regulatory complex, such as the coactivator PCAF96. 
Binding of these factors leads to the increased expression of KLF2 due to the increase 
in shear stress associated with ischemia97,98. Confirming this, work has been done to 
show that indeed a significant up-regulation of KLF2 is seen when high stress 
environments are applied for long periods of time99. The downward trend in expression 
of the KLF2 mRNA seen here indicated a decrease in shear stress has occurred. This 
suggests that 4 weeks of supplementation is sufficient to cause arteriogenic remodeling, 
resulting in an increase in vessel diameter and therefore a decrease in shear stress. 
Interestingly,  findings  have  highlighted  KLF2’s  ability  to  regulate  hypoxia  inducible  factor  
1-alpha (HIF-1α), as KLF2 promotes the degradation of HIF-1α100. Research on HIF-1α 
has shown that at an early time point, such as 30 minutes, increased HIF-1α expression 
is neuroprotective101. This additional mode of neuroprotection gives possible 
explanation to the decrease in KLF2 mRNA seen here. To test shear stress directly we 
plan to continue ongoing research using ultrasound to measure blood flow and 
corrosion cast to find diameter of the vessels, allowing for quantification of shear stress. 
The trend was very close to significance, and we believe that additional future additional 
test subject would be enough to make this statistic significant. Lastly targeted for its role 
in arteriogenesis through shear stress is PCAF. This transcriptional coactivator acts as 
a master switch equipped with histone acetyltransferase activity57. PCAF can acetylate 
both histone proteins and modulate nonhistone proteins, including those of the notch 
pathway mentioned previously102. Results here show a lack of response to TCT 
supplementation. 
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Another group of markers tested in this study were the chloride intracellular channel 
(CLIC) genes. Our previous research in a canine model has also indicated that CLICs 
are sensitive to TCT supplementation. There is also research to show CLICs role in 
collateral reformation31,103. These Chloride intracellular channel proteins are required for 
endothelial cell hollowing50, which is essential for the vascular remodeling process. With 
this, we tested both CLIC1 and CLIC4 in the 4-week supplementation study. Our current 
work revealed no change in mRNA expression for either of the CLIC markers. 
 
The current work leverages laboratory expertise with complex surgical models (rodent 
MCAO) and cutting edge technologies for cell and site specific resolution of tissue 
biology (Laser Capture Microdissection). While these approaches strengthen the work 
overall, they are not without their own limitations which are considered here. First and 
foremost, our surgical stroke model possesses strengths and weaknesses, which have 
been widely studied104-107. An advantage of the intraluminal suture model of middle 
cerebral artery occlusion is that it demonstrates a very good representation of ischemic 
stroke in nature. The method allows the restoration of blood flow after the induction of 
ischemia, which mimics the series of events in human stroke and allows for assessment 
of reperfusion108, though this is not utilized in our project, as we euthanized during 
ischemia. Additionally, this is the most widely used stroke model in research, allowing 
for widespread comparison to other stroke research109. Limitations of the model include 
variability of infarct size and location, high mortality rate, hemmorraging107, and all 
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complications that may result from a surgical procedure such as infection, 
immunodepression110,111, hyperthermia112,113, and loss of body weight114,115. Despite all 
of these limitations, the MCAO stroke model is still the most widely used and 
reproducible rodent model for acute ischemic stroke research. Of note, our laboratory 
takes additional measures to improve reproducibility and mitigate some of the 
aforementioned limitations. The use of laser doppler flowmetry is utilized to measure 
decrease in blood flow. This allows for increased consistency in the size and location of 
stroke. 
 
Our use of laser capture microdissection also warrants consideration. One benefit of 
this technique in relation to our study, is that it allows for selective isolation of 
endothelial tissue. Without this, we would be forced to use whole tissue, and have to 
deal with much larger contamination of samples by non-specific glial and neuronal cells. 
Overall, this selective extraction of desired cells from heterogeneous tissues allows for 
improved subsequent molecular analyses116. As this technique allows for increased 
selectivity in cell type, it results in increased specificity of isolated RNA for downstream 
testing117. This technique also comes with inherent downside. One such negative is 
degradation of RNA due to slide handling and procurement procedures. As necessitated 
by our protocol, slides and tissue are exposed to solutions required for dehydration, 
staining, and other preparations as outlined in materials and methods. All of these steps 
pose increased risk and time of exposure to RNase activity. To combat these risks, we 
treat slides with RNaseZap (Ambion, Austin, TX, USA) before sectioning, and used 
RNAlater (Ambion, Austin, TX, USA) once sections are mounted on the slides. Both 
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these techniques aid in the inactivation of RNase activity, aiding in the stabilization of 
the RNA. The entire LCM process requires a large amount of time while on the 
microscope, subjecting samples to greater risk of RNA degradation. In recognition of 
this limitation, for the current study we limited collection of endothelial cells to 30min per 
slide. Another problem is the amount of tissue collected. As the technique calls for 
selection of only specific cell types, the amount of tissue collected for downstream 
testing is vastly decreased as compared to ground whole tissue preparations. The 
decrease in tissue quantity is mirrored by lower RNA yields, leading to difficulties with 
further analysis of gene expression. To minimize these issues we optimized our protocol 
for collection for up to 2.1*10^5 µm2. We also sought to increase the amount of tissue 
collected by increasing section thickness to 12 µm. These strategies allowed for 
successful yields of RNA necessary for downstream testing. 
 
Our novel immunohistological approach using CD31 and FITC-lectin staining of 
analyzing for quantification of stroke must also be considered. The approach enables 
visualization of perfused vessels in the stroke-affected hemisphere along with direct 
comparison to the contralateral hemisphere. Through immunohistochemical analyses, 
this approach provides quantitative analyses of collateral improvement in the stroke-
affected hemisphere. On the other hand, these staining techniques are not always 
accurate, and it is possible that not every vessel was stained. Contributing to this, there 
is a varied amount of endothelial cell markers present in the vascular bed, and this is 
constantly in fluctuation due to a combination of factors, including vessel size, 
anatomical compartment differences within organ, and presence of pathological 
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conditions118. In addition to the staining of vessels, the software program that analyzes 
the stains has limitations. The program uses automated selection and quantification 
processes that can over- or under-estimate vessels that can be seen by the user, or 
mark background stain that are not indicative of a stained vessel as intended. To 
combat this the mosaic images used on the scope have been adjusted to maximize the 
software’s  recognition  of  stained  regions. 
 
Now with our insight into the outcomes from mRNA gene expression analyses, we have 
new testable hypotheses and strong starting points for additional studies to be 
conducted in the future. First we plan to look at activity of pro-arteriogenic enzymes 
identified here and listed throughout this discussion. An understanding of enzyme 
activity will help shed greater light on the how it is that TCT is able to induce 
arteriogenic remodeling of cerebrovasculature. These future studies hold grave 
importance in both the protease and shear stress pathways studied within this research. 
Secondly, use of corrosion casts to directly measure vessel growth and diameter hold 
great promise. With this information, as well as blood flow through larger vessels as 
measured by ultrasound, we could calculate shear stress, and directly measure its 
change throughout a study to see its overall effect. Finally, we will continue to study the 
role played by TIMP1 in both TCT supplementation and arteriogenesis. We plan to 
utilize TIMP1 knockout mice in order to test the significance of TIMP1 on stroke related 
damage. Of further interest is whether TCT supplementation in TIMP1 knockout still 
attenuates stroke-induced brain injury. If not, outcomes will suggest that TIMP1 is 
essential for TCT-mediated protection against stroke. Overall, the project provides new 
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insight into mechanisms of arteriogenesis in response to TCT supplementation, and 
gives direction to a multitude of future research projects. 
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